Friday, May 12, 2017 11:01:08 AM
Here is my email and their response
______________________
?
Shalom Shmuel,
We spoke on the phone and i asked you some questions that you requested i put into email.
1) when will the psoriasis study be
completed ?
2) when will the results be published?
3) will there be dilution to raise
money for production?
G
Sent via the Samsung Galaxy S7, an AT&T 4G LTE smartphone
:
Hi G
First , thank you for contacting us .
I will try and stay as short and to the point as possible. All your 3 questions below will either get us providing inside information which we can't share or throw speculations .
For instance: we are currently conducting a safety study . You are asking us to assume a definite deadline, so allow me to describe you with what actual safety study ( or FDA phase 1 ) is:
1. Picking up heathy volunteers , that has to respond to an ADD , and prove they are not associated with the company or its competitors
2. Getting them through long physical and mental checkup to secure their healthiness
3. Have them attend the hospital twice a week for 3 months to go through the double blinded random study .
What's happening if one or some of them get sick / pregnant / tired / has to fly urgently out of the country/ ? How can you predict absolute ending time ? Too many external factors can influence timing !
General:
OWC pharmaceutical research is a biotech company and not a toy manufacturer in an automated China production line .
I am sure you realize that R&D and exploring new inventions is unknown road . It's a road we have to build .
Luckily for you as a shareholder and us as a company our pre-clinical phase for the cream's efficacy study led to findings that ( being very careful) are unique , with no previous records of any scientific findings , even remotely close to what we found ! Up to 70% reduction of biological markers directly related to psoriasis.
FYI , pre-clinical = on human tissues but not on human beings .
We are also aware of many "web-speculations" on timing and scientific course , and other imaginary analyses made by "self crowned experts ". None of them is supported by any of the official company's filings or communications. I urge you to rely only on what company is publishing !
Last
Our main focus right now Is :
* complete including our pre-clinical findings into our IP so it will be stronger and un breakable. ( we announced)
* follow up to the vested interest we generated with international organizations ( commercial and scientific) after we announced the pre clinical findings . Allow us to carefully state that this is the real and only prove to the value of our findings .
* continue the preparations to get our product to the market
So forgive us , in advance , if we don't answer fast enough ....we need to work in order to get where you expect us to get....
Have a blessed weekend
Shabat Shalom
Amir Uziel
OWC pharmaceutical research corp .
Business development
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM